Eyepoint Inc $EYPT

Recent News (17)

• INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc. - EYPT PR Newswire · 03 Sep 2026 NEW YORK, Sept. 3, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of EyePoint, Inc. ("EyePoint" or the "Company") (NASDAQ: EYPT). Such investors are advised to conta…
• EyePoint Announces Participation at Upcoming Investor Conferences and Scientific Meeting GlobeNewswire · 02 Sep 2026 WATERTOWN, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients wit…
• TD Cowen downgrades EyePoint stock to Hold on trial concerns Investing.com · 02 Sep 2026 TD Cowen downgrades EyePoint stock to Hold on trial concerns
• EYPT ALERT: Investigation Launched into EyePoint, Inc., Investors are Encouraged to Contact KTMC Law Firm PR Newswire · 28 Aug 2026 RADNOR, Pa., Aug. 28, 2026 /PRNewswire/ -- Kessler Topaz Meltzer & Check, LLP (www.ktmc.com), a nationally recognized securities litigation law firm, is investigating potential violations of the feder…
• INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc. - EYPT PR Newswire · 27 Aug 2026 NEW YORK, Aug. 27, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of EyePoint, Inc. ("EyePoint" or the "Company") (NASDAQ: EYPT). Such investors are advised to conta…
• EyePoint After LUGANO: Primary Endpoint Miss, Asymmetric Risk-Reward (NASDAQ:EYPT) Seeking Alpha · 27 Aug 2026 EyePoint After LUGANO: Primary Endpoint Miss, Asymmetric Risk-Reward (NASDAQ:EYPT)  Seeking Alpha
• EyePoint Pharmaceuticals (EYPT) Securities Investigation Notice - Levi & Korsinsky PR Newswire · 26 Aug 2026 EyePoint Pharmaceuticals shares opened down approximately 70% after the Company disclosed that DURAVYU missed the prespecified primary endpoint in the Phase 3 LUGANO trial. Levi & Korsinsky is investi…
• EYPT SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving EyePoint Pharmaceuticals PR Newswire · 20 Aug 2026 EyePoint Pharmaceuticals told investors its Phase 3 wet AMD program was "on track" days before disclosing that DURAVYU missed the prespecified primary endpoint. SueWallSt notifies investors of a pendi…
• EyePoint’s Regulatory Overhang May Take Time To Clear After Wet AMD Trial Setback, RBC Says – Retail Calls EYPT Slump A ‘Huge Overreaction’ Stocktwits · 18 Aug 2026 EyePoint’s Regulatory Overhang May Take Time To Clear After Wet AMD Trial Setback, RBC Says – Retail Calls EYPT Slump A ‘Huge Overreaction’  Stocktwits
• NKE, META, IVF, EYPT, MU: 5 Trending Stocks Today - Micron Technology (NASDAQ:MU) Benzinga · 18 Aug 2026 NKE, META, IVF, EYPT, MU: 5 Trending Stocks Today - Micron Technology (NASDAQ:MU)  Benzinga
• EyePoint shares plummet after phase 3 stumble for AMD drug-device combo Duravyu Fierce Pharma · 17 Aug 2026 EyePoint shares plummet after phase 3 stumble for AMD drug-device combo Duravyu  Fierce Pharma
• Jefferies cuts EyePoint stock price target to $8 on trial miss Investing.com · 17 Aug 2026 Jefferies cuts EyePoint stock price target to $8 on trial miss
• EyePoint’s Phase 3 fail sends stock spiraling amid next-gen AMD race BioSpace · 17 Aug 2026 EyePoint’s Phase 3 fail sends stock spiraling amid next-gen AMD race  BioSpace
• EYPT Stock On Track To Hit 16-Month Lows After Wet AMD Trial Setback – Retail Sees Ocular Therapeutics As A Better Buyout Candidate tradingview.com · 17 Aug 2026 EYPT Stock On Track To Hit 16-Month Lows After Wet AMD Trial Setback – Retail Sees Ocular Therapeutics As A Better Buyout Candidate  tradingview.com
• EYPT Stock On Track To Hit 16-Month Lows After Wet AMD Trial Setback – Retail Sees Ocular Therapeutics As A Better Buyout Candidate Stocktwits · 17 Aug 2026 EYPT Stock On Track To Hit 16-Month Lows After Wet AMD Trial Setback – Retail Sees Ocular Therapeutics As A Better Buyout Candidate  Stocktwits
• EyePoint’s DURAVYU misses primary endpoint in wet AMD trial Investing.com · 17 Aug 2026 EyePoint’s DURAVYU misses primary endpoint in wet AMD trial
• EyePoint Announces Topline Data from LUGANO, the First of Two Pivotal Phase 3 Clinical Trials for DURAVYU™ 2.7mg in Wet AMD GlobeNewswire · 17 Aug 2026 – DURAVYU was non-inferior to on-label aflibercept control (nominal p-value = 0.0096) in an ad hoc analysis excluding a 4% asymmetric cohort (9 of 211 patients) who experienced vision loss (≥ 15 lette…